C4 Therapeutics (CCCC) Projected to Post Earnings on Thursday

C4 Therapeutics (NASDAQ:CCCC) is expected to announce its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.43) per share for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, February 27, 2026 at 12:30 PM ET.

C4 Therapeutics Stock Up 4.4%

NASDAQ:CCCC opened at $1.91 on Thursday. The company has a market capitalization of $185.10 million, a PE ratio of -1.14 and a beta of 2.96. C4 Therapeutics has a 52-week low of $1.09 and a 52-week high of $3.65. The stock’s 50 day moving average price is $2.06 and its 200 day moving average price is $2.35.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on CCCC. Weiss Ratings restated a “sell (d-)” rating on shares of C4 Therapeutics in a research report on Wednesday, January 21st. TD Cowen started coverage on shares of C4 Therapeutics in a research note on Tuesday, December 2nd. They set a “buy” rating for the company. Finally, Barclays lowered their price objective on shares of C4 Therapeutics from $10.00 to $5.00 and set an “overweight” rating on the stock in a research report on Wednesday, December 17th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $7.25.

Hedge Funds Weigh In On C4 Therapeutics

A number of large investors have recently bought and sold shares of the company. RA Capital Management L.P. acquired a new stake in C4 Therapeutics in the 4th quarter valued at about $15,280,000. Wasatch Advisors LP grew its position in shares of C4 Therapeutics by 10.4% in the second quarter. Wasatch Advisors LP now owns 7,424,662 shares of the company’s stock valued at $10,617,000 after purchasing an additional 700,253 shares during the last quarter. Bain Capital Life Sciences Investors LLC increased its stake in shares of C4 Therapeutics by 545.0% during the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 7,171,910 shares of the company’s stock worth $13,698,000 after purchasing an additional 6,060,000 shares in the last quarter. Vanguard Group Inc. raised its position in shares of C4 Therapeutics by 5.7% during the 3rd quarter. Vanguard Group Inc. now owns 3,191,557 shares of the company’s stock worth $7,085,000 after purchasing an additional 173,535 shares during the last quarter. Finally, Bank of America Corp DE raised its position in shares of C4 Therapeutics by 2.2% during the 3rd quarter. Bank of America Corp DE now owns 2,053,162 shares of the company’s stock worth $4,558,000 after purchasing an additional 45,158 shares during the last quarter. Hedge funds and other institutional investors own 78.81% of the company’s stock.

C4 Therapeutics Company Profile

C4 Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degraders. Utilizing its proprietary Controlled Inducible Degradation (CiD) platform, the company seeks to eliminate disease-causing proteins by harnessing the body’s natural protein disposal machinery. This approach aims to address a wide range of oncology and immuno-oncology indications by targeting proteins that have historically been difficult to inhibit with traditional small molecules or antibodies.

The company’s pipeline includes multiple small-molecule degrader candidates advancing through preclinical and clinical stages.